Catalent, which provides delivery technologies and development solutions for drugs, biologics and consumer health products, announced a major expansion of its manufacturing operations in Bloomington.
The company plans to invest $200 million to expand its biologics manufacturing capacity and drug product fill/finish capacity. It will expand fill/finish capacity at the Bloomington site by 79,000 sq. ft.
A high-speed flexible vial line, utilizing both ready-to-use components and bulk filling, at a filling speed of 300 units per minute, will be installed along with a high-speed flexible syringe/cartridge line with a filling speed of over 300 units per minute, and a fully automated vial inspection machine, the company said in a press statement.
Construction is expected to be completed in April 2019.
Last month, Catalent announced nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington biologics manufacturing facility. Construction of the 15,000-sq.-ft. facility infrastructure is due to be completed in February 2019.